
Nov 6, 2026
Ernexa Therapeutics Reports $12.5M Net Loss and Goodwill Impairment in Q3 2026
Ernexa Therapeutics Inc. reported a net loss of $2,941 thousand for Q3 2026 and $12,456 thousand for the first nine months of 2026, alongside a $2,044 thousand goodwill impairment. The company also saw increased operating expenses, including research and development, but improved its cash position and total assets. Its shares outstanding significantly expanded, and additional paid-in capital rose.
Company relevance
100.00%
Company sentiment
Bearish
Overall sentiment
Bearish